Myeloma News

MRIs and lumbar punctures may not provide enough therapeutic value to be standard-of-care diagnostic tests in patients suffering neurologic symptoms following chimeric antigen receptor T-cell therapy.

The FDA approved ciltacabtagene autoleucel for earlier use in certain adults with relapsed or refractory multiple myeloma.

The FDA has approved Bristol Myers Squibb and 2seventy bio’s idecabtagene vicleucel for treatment of patients with triple-class exposed relapsed or refractory multiple myeloma, according to a company release.

Within the past 2 decades, multiple myeloma has shifted from a highly lethal diagnosis to a condition that will no longer shorten the lifespan for many patients.

More than 20% of reported cases of adverse events following bispecific T-cell engager therapies involved a cardiovascular event, findings reported in Journal for ImmunoTherapy of Cancer showed.

Most of the major cancer clinical trial centers in the U.S. are located near more affluent and white populations compared with the national average, according to results published in JAMA Oncology.

An FDA advisory committee voted that a pair of chimeric antigen receptor T-cell therapies should be approved for earlier line treatments in adults with relapsed or refractory multiple myeloma, although one produced far more deliberation.

Researchers at Mayo Clinic have identified clinical factors associated with increased risk for developing myeloid neoplasms following chimeric antigen receptor T-cell therapy, according to data published in JAMA Oncology.

Regardless of vaccination status, individuals with hematologic malignancies had increased odds of developing severe COVID-19 until oral antivirals became widely available in mid-2022, according to data published in JAMA Network Open.